BR112022009181A2 - Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t - Google Patents
Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula tInfo
- Publication number
- BR112022009181A2 BR112022009181A2 BR112022009181A BR112022009181A BR112022009181A2 BR 112022009181 A2 BR112022009181 A2 BR 112022009181A2 BR 112022009181 A BR112022009181 A BR 112022009181A BR 112022009181 A BR112022009181 A BR 112022009181A BR 112022009181 A2 BR112022009181 A2 BR 112022009181A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- product
- bank
- cell product
- providing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 238000013411 master cell bank Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
SISTEMA PARA PROVER UM PRODUTO DE CÉLULA T, MÉTODOS PARA PRODUZIR UM PRODUTO DE CÉLULA T, PARA CONSTRUIR UM BANCO CELULAR E UMA COLEÇÃO DE PRODUTO DE CÉLULA T E PARA PROVER UM PRODUTO DE CÉLULA T, BANCO CELULAR, COLEÇÕES DE BANCO CELULAR E DE PRODUTO DE CÉLULA T, E, PRODUTO DE CÉLULA T. A presente invenção provê um sistema para prover produtos de célula T, incluindo um banco celular mestre de célula T e/ou um banco celular de trabalho de célula T.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019212718 | 2019-11-25 | ||
PCT/JP2020/043573 WO2021106832A1 (ja) | 2019-11-25 | 2020-11-24 | T細胞マスターセルバンク |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009181A2 true BR112022009181A2 (pt) | 2022-07-26 |
Family
ID=76130245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009181A BR112022009181A2 (pt) | 2019-11-25 | 2020-11-24 | Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230000915A1 (pt) |
EP (1) | EP4067490A4 (pt) |
JP (1) | JPWO2021106832A1 (pt) |
KR (1) | KR20220106975A (pt) |
CN (1) | CN114761560A (pt) |
AR (1) | AR120538A1 (pt) |
AU (1) | AU2020393334A1 (pt) |
BR (1) | BR112022009181A2 (pt) |
CA (1) | CA3162755A1 (pt) |
CO (1) | CO2022007926A2 (pt) |
IL (1) | IL293189A (pt) |
MX (1) | MX2022006288A (pt) |
TW (1) | TW202134429A (pt) |
WO (1) | WO2021106832A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2022059780A1 (pt) * | 2020-09-18 | 2022-03-24 | ||
WO2022220146A1 (ja) * | 2021-04-16 | 2022-10-20 | サイアス株式会社 | T細胞受容体遺伝子を導入するためのiPS細胞により構成される細胞バンク |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
AU2001248162B2 (en) | 2000-04-03 | 2007-02-01 | Hemosol Lp. | Production of TcR gamma delta T cells |
MXPA06011371A (es) | 2004-04-10 | 2006-12-20 | Henkel Kgaa | Tubo para rizar el cabello. |
EP4223769A3 (en) | 2005-12-13 | 2023-11-01 | Kyoto University | Nuclear reprogramming factor |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US7661738B2 (en) | 2006-11-28 | 2010-02-16 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
US9382515B2 (en) | 2007-04-07 | 2016-07-05 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
US20100184051A1 (en) | 2007-05-30 | 2010-07-22 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
EP2172547B1 (en) | 2007-06-11 | 2016-01-06 | Takara Bio Inc. | Method for expression of specific gene |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
US20130101567A1 (en) * | 2010-04-08 | 2013-04-25 | The Trustees Of The University Of Pennsylvania | Methods to Expand a T Regulatory Cell Master Cell Bank |
CA2805442C (en) * | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
JP6344821B2 (ja) | 2011-11-21 | 2018-06-20 | ユニバーシティ・ヘルス・ネットワーク | 造血前駆体の集団および造血前駆体のための幹細胞を富化する方法 |
WO2013176197A1 (ja) * | 2012-05-22 | 2013-11-28 | 国立大学法人 東京大学 | 抗原特異的t細胞の製造方法 |
EP3964567A1 (en) * | 2012-05-25 | 2022-03-09 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
KR102228828B1 (ko) * | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
AU2015249371B2 (en) * | 2014-04-24 | 2020-04-30 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
WO2016076415A1 (ja) | 2014-11-13 | 2016-05-19 | 国立大学法人京都大学 | 多能性幹細胞からt細胞への誘導方法 |
GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
MX2017013247A (es) * | 2015-04-15 | 2018-08-15 | Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center | Infusion arterial hepatica de linfocitos t car. |
AU2016349504B2 (en) * | 2015-11-04 | 2023-02-09 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
AU2016361451B2 (en) | 2015-11-27 | 2024-01-25 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
JP2019080491A (ja) * | 2016-03-16 | 2019-05-30 | 国立大学法人京都大学 | 免疫細胞療法用ny−eso1抗原特異的t細胞の誘導方法 |
WO2017221975A1 (ja) | 2016-06-23 | 2017-12-28 | 国立大学法人京都大学 | Cd4cd8両陽性t細胞の製造方法 |
EP3269739A1 (en) * | 2016-07-15 | 2018-01-17 | OGD2 Pharma | Humanized antibody against o-acetylated gd2 ganglioside (oacgd2) |
AU2017326748A1 (en) * | 2016-09-14 | 2019-04-11 | Benitec Biopharma Limited | Reagents for producing T-cells with non-functional T-cell receptors (TCRs) compositions comprising same and use thereof |
CN111094349A (zh) * | 2017-08-23 | 2020-05-01 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 嵌合抗原受体和结合cxcr5的car-t细胞 |
CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
JP7259215B2 (ja) | 2018-06-01 | 2023-04-18 | 富士電機株式会社 | 絶縁ゲート型半導体装置及び絶縁ゲート型半導体装置の製造方法 |
-
2020
- 2020-11-24 KR KR1020227017516A patent/KR20220106975A/ko unknown
- 2020-11-24 IL IL293189A patent/IL293189A/en unknown
- 2020-11-24 CN CN202080081737.4A patent/CN114761560A/zh active Pending
- 2020-11-24 AR ARP200103251A patent/AR120538A1/es unknown
- 2020-11-24 CA CA3162755A patent/CA3162755A1/en active Pending
- 2020-11-24 MX MX2022006288A patent/MX2022006288A/es unknown
- 2020-11-24 TW TW109141143A patent/TW202134429A/zh unknown
- 2020-11-24 JP JP2021561399A patent/JPWO2021106832A1/ja active Pending
- 2020-11-24 EP EP20893086.7A patent/EP4067490A4/en active Pending
- 2020-11-24 BR BR112022009181A patent/BR112022009181A2/pt unknown
- 2020-11-24 AU AU2020393334A patent/AU2020393334A1/en active Pending
- 2020-11-24 WO PCT/JP2020/043573 patent/WO2021106832A1/ja unknown
- 2020-11-24 US US17/778,611 patent/US20230000915A1/en active Pending
-
2022
- 2022-06-03 CO CONC2022/0007926A patent/CO2022007926A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3162755A1 (en) | 2021-06-03 |
CO2022007926A2 (es) | 2022-06-30 |
TW202134429A (zh) | 2021-09-16 |
US20230000915A1 (en) | 2023-01-05 |
AR120538A1 (es) | 2022-02-23 |
AU2020393334A1 (en) | 2022-06-16 |
EP4067490A4 (en) | 2024-02-21 |
EP4067490A1 (en) | 2022-10-05 |
JPWO2021106832A1 (pt) | 2021-06-03 |
CN114761560A (zh) | 2022-07-15 |
KR20220106975A (ko) | 2022-08-01 |
MX2022006288A (es) | 2022-06-08 |
IL293189A (en) | 2022-07-01 |
WO2021106832A1 (ja) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018318303A1 (en) | Antigen-binding proteins targeting shared antigens | |
MX2020000960A (es) | Anticuerpos anti-tigit. | |
EP3649965A3 (en) | Surgical instrument comprising separate tissue securing and tissue cutting systems | |
MX2020003125A (es) | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. | |
MX2019006868A (es) | Derivados de polisacáridos anfifílicos y composiciones que los comprenden. | |
BR112022009181A2 (pt) | Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t | |
WO2016105450A3 (en) | Trispecific antibodies | |
BR112017017086A2 (pt) | monitoramento de produtos de escavação para equipamento de terraplenagem | |
EP3765522A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES | |
WO2018089261A3 (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
WO2017031360A8 (en) | Capture of nucleic acids using a nucleic acid-guided nuclease-based system | |
MX2017008254A (es) | Herramienta o parte de herramienta, sistema que incluye dicha herramienta o parte de herramienta, metodo para producir dicha herramienta o parte de herramienta y metodo para moldear un producto a partir de una suspension de pulpa. | |
WO2019204632A8 (en) | Method and system for rapid genetic analysis | |
EP4219526A3 (en) | Method for preparing amg 416 | |
WO2019118829A3 (en) | Sialyltransferases and uses thereof | |
WO2017171441A3 (ko) | 페라이트계 촉매, 이의 제조방법 및 이를 이용한 부타디엔의 제조방법 | |
MY148546A (en) | Biocidal polymers | |
MX2020003262A (es) | Indicador biologico. | |
EP3141598A3 (en) | Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them | |
EP3919347A4 (en) | TRAIN SAFETY SYSTEM | |
MX2021008216A (es) | Anticuerpos anti-tigit. | |
AU2018339067A1 (en) | Message-credentialed blockchains | |
EP3859083A4 (en) | HYDROPHOBIZING APPARATUS BY HEAT PRESS GAS Grafting, AND ECO-FRIENDLY LIGHTWEIGHT OIL-ABSORBENT PAPER MADE THEREOF | |
EP3854900A4 (en) | STEEL ELEMENT, STEEL SHEET AND METHOD OF PRODUCTION THEREOF | |
WO2019071021A3 (en) | Immunomodulatory oligosaccharides |